Default company panoramic image

ForeSight Dx

Finalizing development of the Industry’s first blood-based test for Alzheimer’s Disease (AD)and Mild Cognitive Impairment (MCI).

  • Stage Product In Development
  • Industry Biotechnology
  • Location Scottsdale, AZ, USA
  • Currency USD
  • Employees 2
  • Website

Company Summary

ForeSight Dx has licensed a new and highly unique protein-based biomarker for the early detection of Alzheimer’s disease and mild cognitive impairment. NIH funded studies have shown this biomarker to be significantly more accurate than the Aβ biomarkers currently on the market. This test can be used with patient samples of either cerebrospinal fluid, or blood. No blood-based test for AD exists in the marketplace today.


  • Default avatar
    Brad Fox

    Brad has over 25 years of experience in life science start ups with operational management expertise.

  • Default avatar
    Michael Hull

    Mike has 25 years of experience in financial management including international expertise and a long term Angel who has worked with numerous start-ups on product development, funding and sale of technologies.

  • Default avatar
    Dr. Marwan Sabbagh
    KOL - Chief Clinical Advisor

    Dr. Sabbagh is ForeSight’s Key Opinion Leader and Clinical Advisor. Dr. Sabbagh is the founding director of the Cleo Roberts Center for Clinical Research under the umbrella of the Sun Health Research Institute and has conducted over 50 clinical trials in Alzheimer’s and Parkinson’s disease. Dr. Sabbagh reviews all of ForeSight’s technology and clinical developments and will have the first publishing rights on clinical outcomes.


  • Default avatar
    Michael Hool